Charged Alpha Stock Encyclopedia

Colton Thomas
  • 0.0 (0)
  • Investing

⚡ Charged Alpha — The S&P 500 Stock Encyclopedia Data-driven deep dives into every stock in the S&P 500 after every earnings report. Each episode breaks down one company from open to close: what they do, how the numbers look, what Wall Street thinks, the bull case, the bear case. 🛠️ Check out our free beginner-friendly screening tools for stocks, ETFs, options, crypto, bonds, REITs & more at https://chargedalpha.com — no signup, no paywall. 📊 What you get in every episode: Company overview & competitive moat Full financial breakdown — valuation, revenue, margins, cash flow Analyst consensus & price targets Bull case vs. bear case Peer comparison, options flow & insider activity Key metrics to watch ⚠️ Not financial advice. For educational purposes only. Episodes are researched, written, and produced using AI-assisted tools. All data aggregated from publicly available sources. #stocks #investing #S&P500 #stockanalysis #chargedalpha #financialdata #earningsreport #earnings

  1. 1d ago

    GE Vernova Stock: Orders Just Exploded +88% and It RAISED Guidance — So Why We Say HOLD

    GE Vernova (GEV) Q2 2026 — GE Vernova (GEV), the power-and-grid company spun out of the old General Electric, reported a blockbuster Q2 2026: orders exploded +88% organically to $24.2B, revenue rose 22% to $11.1B (+12% organic), adjusted EBITDA jumped to $1.25B (an 11.3% margin, +340bps organic), and free cash flow hit $5.1B — more than all of 2025. Management RAISED full-year guidance, nearly DOUBLING the free-cash-flow outlook to $11.5–12.5B and lifting revenue to $45.5–46.5B, on a $176B backlog. GAAP EPS was $2.47 (+33% YoY), a touch light versus the Street's number. The stock (~$1,079, flat on the print) has roughly doubled off its $530 low and sits ~10% below its $1,196 high. The catch: at ~48x adjusted EBITDA, even our optimistic supercycle DCF lands fair value near $800 — below the price — because much of that free cash flow is customer advance payments that normalize. Our call: HOLD, 3/5. GE Vernova is the market's purest play on the electricity supercycle — the energy business carved out of the old General Electric in 2024, selling exactly what AI data centers, reshoring, and electrification suddenly can't get enough of: gas turbines and grid equipment. Q2 2026 was a blowout on the metrics that matter: orders exploded +88% organically to $24.2B, revenue rose 22% to $11.1B (+12% organic), adjusted EBITDA jumped to $1.25B (an 11.3% margin, up 340bps organically), and free cash flow surged to $5.1B — more than all of 2025. Power orders rose +134% (gas equipment under contract went from 100 to 116 GW, targeting 125+ by year-end); Electrification revenue grew +68% with a ~1.7 book-to-bill; only Wind lagged (revenue −10%, losses widening). Management RAISED guidance again — nearly DOUBLING the FCF outlook to $11.5–12.5B and lifting revenue to $45.5–46.5B — on a $176B backlog. GAAP EPS was $2.47 (+33% YoY), a touch light vs the Street. So the debate isn't quality — it's price. The stock has roughly doubled off its $530 low to ~$1,079, ~48x adjusted EBITDA. Here's the honest nuance: a big slice of that gorgeous free cash flow is customer down-payments on the booming gas backlog — advance payments that flatter cash today and normalize as turbines ship. Strip them out and anchor on normalized owner earnings (~$4.5B), and even our optimistic supercycle DCF lands fair value near $800 — below today's price; even the supercycle path at a 9% discount rate is only ~$1,025, still under the stock. A wonderful business with no margin of safety. Our call: HOLD, 3/5. We're not sellers of a compounder this good, but at these levels we wouldn't chase it — and we're more cautious than the Street's bullish ~$1,160 target (Buy, 21 of 28 analysts, 0 sells). Own it for the quality, add on real weakness toward $800, and watch margins and cash conversion. Not financial advice. THE CALL: HOLD (3/5, A SUPERCYCLE WINNER, PRICED BEYOND PERFECTION — A BEAT-AND-RAISE WITH NO MARGIN OF SAFETY) — base-case value ~$800 vs ~$1079 today. What to watch: durable margin expansion plus free cash flow that holds up as gas-turbine advance payments normalize — and Wind finally turning profitable — which would prove the cash generation is structural, not just working-capital timing, and justify the premium multiple, prompting an upgrade; the risk to respect is a stall in orders, a crack in the AI-data-center power narrative, or a margin disappointment, which at ~48x adjusted EBITDA could re-rate the stock hard Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  2. 2d ago

    Novartis Stock (NVS): It Beat Q2 AND Returned to Growth — So Why We Say HOLD

    Novartis AG (NVS) Q2 2026 — Novartis (NVS), the ~$285B Swiss pharma giant, reported Q2 2026 before the open on July 21: net sales of $14.4B rose +1% in constant currency (+3% USD) — a RETURN TO GROWTH after Q1's -5% cc decline — and core operating income of $5.94B beat the ~$5.3B consensus at a 41.2% margin. Core EPS of $2.41 beat the $2.17 estimate. But reported (IFRS) EPS fell -17% to $1.71, net income dropped -19% on higher taxes and interest, and free cash flow slipped -12% to $5.6B as net debt DOUBLED to $39.4B on M&A (Avidity, Myricx). Entresto fell -50% to $1.18B as US generics launched, while Kisqali (+43%), Kesimpta (+32%), Scemblix (+89%), Pluvicto (+43%) and Leqvio (+59%) more than filled the hole. FY2026 guidance reaffirmed (net sales grow LSD, core op income decline LSD). The ADR fell ~2.7% to ~$149.56 on the print. Novartis (NVS) is one of the two or three largest drugmakers on earth — a ~$285B Swiss pure-play innovative-medicines company (Aa3/AA-) led by Vas Narasimhan. Q2 2026 was, on the surface, a strong quarter: net sales of $14.4B returned to growth (+1% cc, +3% USD), core operating income of $5.94B beat the ~$5.3B Street estimate at a superb 41.2% margin, core EPS of $2.41 beat $2.17 — and the crown-jewel drug Kisqali won a surprise 6-month FDA pediatric exclusivity. The growth engine (Kisqali +43%, Kesimpta +32%, Scemblix +89%, Pluvicto +43%, Leqvio +59%, Fabhalta +88%) more than absorbed the Entresto patent cliff (-50% to $1.18B on US generics; EU LOE in November). Yet the ADR FELL ~3% on the print. Why? Underneath the polished 'core' numbers, reported IFRS EPS fell -17% to $1.71, net income dropped -19%, and free cash flow slipped -12% — because net debt DOUBLED from $21.9B to $39.4B in six months funding a $15.3B M&A spree. Management reaffirmed a trough-year guide (core operating income to DECLINE low-single-digits in 2026), and both Goldman and Jefferies say the premium multiple now hinges on second-half pipeline readouts. Our owner-earnings DCF (base ~$15.5B FCF, +2%/+5% growth, 7-8-9% discount, less $39.4B net debt, ~1.91B shares) centers near $128 vs the ~$150 price — about 15% below. Our call: HOLD, 3/5. Quality is not the question; the price is. We ALIGN with the Street's Hold (avg target ~$155, ~+4%) but are a shade more cautious. We'd own this fortress cheaper — under ~$120 — not here. Not financial advice. THE CALL: HOLD (3/5, A FORTRESS FRANCHISE THAT RETURNED TO GROWTH — BUT AT ~17x, WITH CORE PROFIT STILL FALLING AND NET DEBT DOUBLED, THE PRICE ALREADY PAYS FOR THE PIPELINE) — base-case value ~$128 vs ~$149.56 today. What to watch: clean wins in the second-half 2026 pipeline readouts (Goldman's bar: at least 2 of 3 major late-stage trials) or a return to core operating-income GROWTH in 2027 would justify the premium multiple and prompt an upgrade; the risks to respect are a guidance cut, a pipeline miss, or generic erosion (Entresto EU LOE in November) out-running the launch brands — watch the growth drivers and readouts each quarter Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  3. 2d ago

    Steel Dynamics Stock: Record Q2, Earnings +84% — But We Say HOLD (STLD Q2 2026)

    Steel Dynamics (STLD) Q2 2026 — Steel Dynamics (STLD), one of the largest U.S. electric-arc-furnace (EAF) steelmakers, reported a RECORD Q2 2026: net sales rose 33% to $6.1B, operating income jumped 83% to $700M, and diluted EPS surged 84% year-over-year to $3.69 — beating the company's own raised guidance of $3.51–$3.55 (even after a $16M non-cash impairment on relocating a planned aluminum site from Arizona to Columbus, Mississippi). Adjusted EBITDA was $921M on record steel shipments of 3.7M tons, as steel selling prices (ASP $1,298/ton, +$105 sequentially) outran ferrous scrap costs ($412/ton, +$16). The company generated $428M of operating cash flow, bought back $200M of stock (~1% of shares), and raised the dividend ~6% to $0.53/quarter. Yet the stock (~$230) sits ~20% BELOW its June 2026 high of $289, after nearly doubling off its 2025 low near $120. On honest mid-cycle math our blended fair value is ~$200 — below today's price. Our call: HOLD. Steel Dynamics is one of the largest and best-run steel producers in the United States — a low-cost electric-arc-furnace (EAF) 'mini-mill' operator that melts recycled scrap rather than smelting iron ore, giving it a structural cost and carbon advantage over legacy blast-furnace mills. It runs ~12M tons of annual steel capacity across four segments — steel operations (the core engine), metals recycling, steel fabrication, and a brand-new aluminum flat-rolled business — and earns a best-in-class ~13% three-year after-tax return on invested capital. Q2 2026 was a genuine blowout: net sales +33% to $6.1B, operating income +83% to $700M, and diluted EPS +84% to $3.69, beating its own raised $3.51–$3.55 guidance. The beat was operational, not accounting: metal spreads widened as steel ASP rose $105/ton to $1,298 while scrap rose just $16 to $412, on record shipments of 3.7M tons, and the steel-fabrication backlog is up 45% YoY into 2027. Segment operating income: Steel $721M, Fabrication $85M, Metals Recycling $48M — and Aluminum a $33M startup loss (narrowing 48% sequentially) as the 650,000-ton Columbus, MS mill ramps toward automotive qualification by end-2026. So why only a HOLD? Because steel is deeply CYCLICAL: today's fat spreads and record earnings sit near a strong point in the cycle, and the stock has already nearly doubled off its 2025 low. Valuing a cyclical on mid-cycle (not peak) owner earnings — normalized FCF of ~$1.75–2.05B/yr, discounted at 8/9/10% and net of ~$3.6B net debt — our two-scenario DCF spans ~$147–$210 (mid-cycle) and ~$191–$272 (up-cycle), blending to ~$200 at 9%, with a ~$150 downside if the cycle rolls over. That's BELOW the ~$230 price: no margin of safety. At ~21x trailing earnings and ~11–12x EV/EBITDA, STLD is fairly valued versus fellow EAF leader Nucor — a premium operator at a premium-operator multiple, not a bargain, with a slim ~0.9% dividend. Our verdict: HOLD, 3/5. A company to admire and a price to wait on — we're more cautious than Wall Street's Buy consensus and ~$272 average target. Not financial advice. THE CALL: HOLD (3/5, A GREAT COMPANY AT A CYCLICAL PRICE — RECORD QUARTER AND REAL ALUMINUM OPTIONALITY, BUT PEAK-ish EARNINGS AND NO MARGIN OF SAFETY AFTER A NEAR-DOUBLE OFF THE LOW) — base-case value ~$200 vs ~$230 today. What to watch: Watch metal spreads (steel ASP vs. ferrous scrap cost) above all else — the single biggest driver of quarterly profit — plus the aluminum ramp (shipments, yields, and the path to sustained profitability into 2027). We'd turn more constructive on a pullback toward ~$185 or below (closer to mid-cycle earnings support), or on clear evidence the 650k-ton aluminum mill is reaching durable profitability while steel spreads hold — which would add a fourth earnings engine and justify a higher value. The risk to respect is the opposite: spreads compressing (scrap rising faster than steel prices) or a construction/industrial slowdown, in which case earnings and the multiple compress together and the stock heads toward the ~$150 downside case. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  4. 5d ago

    Vista Energy Stock (VIST): EBITDA Nearly DOUBLED — So Why the ’Miss’? (Q2 2026)

    Vista Energy (VIST) Q2 2026 — Vista Energy (VIST) reported Q2 2026 (Jul 16): total revenue ~$1.21B (+89% YoY); adjusted EBITDA $805M (+99% YoY) at a 70% margin; production 156,061 boe/d (+32% YoY, ~87% oil), oil 135,427 bbl/d (+33%); realized oil $89.4/bbl (+44% YoY) at a $4.5/boe lifting cost. Reported EPS was $3.0 (+37% YoY, flattered by an acquisition gain), but ADJUSTED EPS of $2.38 MISSED the ~$3.15 consensus - the shortfall was below-the-line, as D,D&A jumped 53% to $271M and taxes doubled while Vista consolidated the Equinor (Bandurria Sur / Bajo del Toro) assets acquired in May. Capex $467M; free cash flow $491M ex-acquisition. Net debt $3.06B; net leverage 1.41x (1.25x pro forma), targeting ~1.0x by year-end. Guidance: ~158k boe/d for 2026 (Q4 ramping toward ~170k) and ~$3.0B adjusted EBITDA at $85 Brent (+/- ~$200M per $10/bbl). The stock is ~$64, about 21% below its $81 high. Our EV/EBITDA work (4x 2026E EBITDA, with a deliberate Argentina discount) lands fair value ~$80. Wall Street: unanimous Buy (6/0/0), ~$85 average target. Our call: BUY, 3/5. Vista Energy is an Argentine oil producer and essentially a pure-play on Vaca Muerta - one of the best shale basins outside the U.S. In Q2 2026 the headline looked like a miss: adjusted EPS of $2.38 landed well short of the ~$3.15 consensus, and yet the operational quarter was a blowout - production up 32% to 156,061 boe/d, revenue up 89%, and adjusted EBITDA up 99% to $805M at a 70% margin. The 'miss' was below the line: reported EPS was actually $3.0 (up 37%, helped by an acquisition gain), but adjusted earnings were dragged by a 53% jump in depreciation (to $271M) and a doubling of taxes as Vista consolidated the Equinor assets (Bandurria Sur and Bajo del Toro) it acquired in May - the accounting cost of scaling up, not a crack in the business. Vista realized $89.40/bbl for its oil at a $4.50/boe lifting cost (one of the lowest anywhere), exports about two-thirds of its crude for hard currency, and generated $491M of free cash flow ex-acquisition. The deal did push net debt to $3.06B and leverage to 1.41x (1.25x pro forma), with management targeting ~1.0x by year-end. 2026 guidance: ~158k boe/d (Q4 toward ~170k) and ~$3.0B adjusted EBITDA at $85 Brent. On EV/EBITDA - the right lens for a commodity producer - Vista trades at barely ~3x this year's EBITDA; at 4x, with a deliberate Argentina discount, fair value is ~$80 vs ~$64 today. Wall Street is a unanimous Buy (6/0/0) with a ~$85 target. Our call: BUY, 3/5 - a cheap, fast-growing, low-cost oil producer, priced for an Argentina risk (FX, export duties, capital controls) that may be overdone but is genuinely un-hedgeable. Not financial advice. THE CALL: BUY (3/5, A CHEAP, FAST-GROWING, LOW-COST VACA MUERTA OIL PRODUCER, PRICED FOR ARGENTINA RISK THAT MAY BE OVERDONE) — base-case value ~$80 vs ~$64 today. KEY METRICS: - Revenue ~$1.21B (+89% YoY); adjusted EBITDA $805M (+99% YoY), 70% margin - Production 156,061 boe/d (+32% YoY, ~87% oil); oil 135,427 bbl/d (+33%) - Realized oil $89.4/bbl (+44% YoY); lifting cost $4.5/boe (world-class low) - Reported EPS $3.0 (+37%, acquisition gain); ADJUSTED EPS $2.38 vs ~$3.15 est (MISS) - D,D&A +53% to $271M, taxes doubled - Capex $467M; free cash flow $491M ex-acquisition; net debt $3.06B; leverage 1.41x (1.25x pro forma) -> ~1.0x target - Equinor deal (Bandurria Sur 25.1% + Bajo del Toro 35%) consolidated from May 1, 2026 - FY2026 guide: ~158k boe/d (Q4 ~170k) and ~$3.0B adjusted EBITDA at $85 Brent (+/-$200M per $10/bbl) - Our EV/EBITDA fair value ~$80 vs ~$64; Wall Street unanimous Buy (6/0/0), ~$85 avg target What to watch: Bullish confirmation: production ramping toward ~170k boe/d in Q4, net leverage falling back toward ~1.0x on free cash flow, and Brent holding near $85 - each would support a re-rating from ~3x toward peer multiples. The thesis breaks on an oil-price sell-off (every $10/bbl of Brent is ~$200M of second-half EBITDA) or an Argentine shock - peso devaluation, harsher export duties, or capital controls. Watch two dials above all: the Brent oil price and the net-leverage line. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  5. 6d ago

    ISRG Stock: Intuitive Surgical BEAT Q2 2026 — So Why Did It Crash 12%? (Cheap at Last, or Value Trap?)

    Intuitive Surgical (ISRG) Q2 2026 — Intuitive Surgical (ISRG) reported a clean Q2 2026 beat: revenue $2.89B (+19% YoY), non-GAAP EPS $2.80 (beat $2.48, +28%), GAAP EPS $2.29; worldwide procedures +16% (da Vinci +15%, Ion +36%); 468 da Vinci systems placed (246 were da Vinci 5) vs 395 a year ago; installed base 11,710 (+12%). Instruments & accessories $1.73B (+18%, ~60% of revenue); non-GAAP gross margin 70.0%; operating margin >40%; $8.63B cash and zero debt; $0.38B buyback. Yet the stock FELL ~12.6% to a fresh 52-week low near $352 — down ~42% from its $604 high — because FY26 da Vinci procedure-growth guidance of 13.5-15.5% marked a clear step down from the high-teens, alongside softer hospital surgery volumes and a da Vinci Class II component recall. Our owner-earnings DCF lands ~$343, essentially on top of the ~$352 price. Wall Street: Buy (39 of 56), avg target ~$525. Our call: HOLD, 3/5 — a premier compounder now at roughly fair value; not a bargain yet. Intuitive Surgical is the pioneer and monopoly of robotic-assisted surgery — the da Vinci system, the Ion lung-biopsy robot, and a razor-and-blade model where over 76% of revenue recurs. In Q2 2026 it delivered a clean beat: revenue $2.89B (+19%), non-GAAP EPS $2.80 (vs $2.48), worldwide procedures +16%, non-GAAP gross margin 70%, and 468 da Vinci placements (246 da Vinci 5), lifting the installed base 12% to 11,710. And yet the stock fell ~12.6% to a fresh 52-week low near $352 — down ~42% from its $604 high. The reason isn't the quarter; it's the guide: FY26 da Vinci procedure growth of 13.5-15.5% (management points to the midpoint) is a step down from the high-teens pace of recent years, compounded by softer hospital volumes and a Class II recall. For a stock still near 33x forward earnings, decelerating procedure growth is the number that matters most. Our owner-earnings DCF (base ~$3.2B/yr, +$8.6B net cash) spans $246-$463 across 8-10% discount rates and 10-14% growth, with a probability-weighted value near $343 — roughly on top of today's ~$352. Wall Street rates it a Buy with a ~$525 target (nearly 50% upside), but even our bullish path only reaches the mid-$400s, and on the Street's own EPS estimates the math lands near our $343. Our call: HOLD, 3/5 — a wide-moat monopoly that has finally de-rated to fair value, but is not yet a bargain. Own the quality; look to add below $300; watch the quarterly procedure line above all else. Not financial advice. THE CALL: HOLD (3/5, A PREMIER SURGICAL-ROBOTICS MONOPOLY — NOW ROUGHLY FAIR, WAIT FOR A BETTER PRICE) — base-case value ~$343 vs ~$352 today. What to watch: da Vinci procedure growth stabilizing and re-accelerating back toward the high-teens (da Vinci 5 lifting procedures per system), which would justify the premium multiple — or, conversely, a pullback below ~$300 that opens a genuine margin of safety and turns us to a buy; the thesis breaks if procedure growth slides below 12% or tariff/competition pressures compress margins Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  6. 6d ago

    ABT Stock: Abbott Beat AND Raised — So Why Is It Still Down 27%? (Bargain or Value Trap?)

    Abbott Laboratories (ABT) Q2 2026 — Abbott (ABT) reported a solid Q2 2026 beat: revenue $12.59B (+13.0% reported, +4.8% organic), adjusted EPS $1.31 (beat $1.28, +4% YoY), adjusted gross margin 58.0% (+100bps). Medical Devices +8.4% (CGM/FreeStyle Libre cleared $2B, +9.5%), Established Pharma +9%, Diagnostics +2.9% organic (+42.3% w/ Exact Sciences), Nutrition -3.6%. It RAISED FY26 adjusted EPS guidance to $5.45-$5.60 and reaffirmed 6.5-7.5% organic growth. Yet the Dividend King (53 yrs, $0.63/qtr) trades ~$101 — down ~27% from its $137 high — on Exact Sciences dilution/leverage (~2.7x) and NEC infant-formula litigation. Abbott is one of the great diversified healthcare compounders — Medical Devices, Diagnostics, Nutrition and Established Pharmaceuticals, anchored by the world's #1 glucose monitor (FreeStyle Libre) and 53 straight years of dividend increases. In Q2 2026 it beat (revenue $12.59B, +4.8% organic; adjusted EPS $1.31 vs $1.28) and RAISED full-year EPS guidance to $5.45-$5.60 while reaffirming 6.5-7.5% organic growth. The growth engine is diabetes care: CGM sales cleared $2B, +9.5%, with the new Libre Duo glucose-ketone sensor. Yet the stock is still down ~27% from its $137 high, de-rated to ~18x forward earnings on three overhangs: the $21B Exact Sciences acquisition (dilutive ~$0.20, leverage ~2.7x), ~1,000 NEC infant-formula lawsuits ($495M verdict under appeal), and a shrinking Nutrition segment (-3.6%). Our owner-earnings DCF lands near $110 (vs ~$101), with the bull path at ~$122 — right on the Street. Our call: BUY, 3/5 — a de-rated, wide-moat compounder that just beat and raised; quality on sale with a modest margin of safety. Accumulate on weakness in the low $90s; watch the NEC litigation and organic re-acceleration. Not financial advice. THE CALL: BUY (3/5, A DE-RATED COMPOUNDER — QUALITY ON SALE, MIND THE OVERHANGS) — base-case value ~$110 vs ~$101 today. What to watch: organic growth re-accelerating to the reaffirmed 6.5-7.5% guide (Diagnostics lapping the weak respiratory season, Nutrition stabilizing, CGM staying double-digit), the Exact Sciences deal turning accretive, and dips toward the low $90s (near the 200-day) as add points Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  7. 6d ago

    GE Aerospace Stock: It Beat Earnings and RAISED Guidance Again — So Why We Say HOLD

    GE Aerospace (GE) Q2 2026 — GE Aerospace (GE), the pure-play jet-engine giant carved out of the old General Electric, reported a strong Q2 2026: adjusted EPS of $2.02 beat the ~$1.86 estimate (+22% YoY) on adjusted revenue of $12.6B (+24%), orders jumped 17% to $16.5B, operating profit rose 18% to $2.7B, and free cash flow surged 43% to $3.0B. Management RAISED full-year 2026 guidance again — adjusted EPS to $7.65–$7.85 and free cash flow to $8.9–$9.2B — backed by a $210B+ backlog. The stock (~$354, up ~2.4% on the print) has nearly doubled off its $255 low and sits ~8% below its $383 high. The catch: at ~45x forward earnings and ~41x free cash flow, even our optimistic aftermarket-compounder DCF lands near $290 — below the price. Our call: HOLD. GE Aerospace is one of the market's great comeback stories — the old General Electric, broken up and reborn as a focused, ~$370B pure-play jet-engine maker led by Larry Culp. Q2 2026 was a genuinely strong quarter: adjusted EPS of $2.02 beat the ~$1.86 estimate (+22% YoY), adjusted revenue rose 24% to $12.6B, orders jumped 17% to $16.5B, free cash flow surged 43% to $3.0B, and — for the second time this year — management RAISED full-year guidance across the board (adj EPS $7.65–$7.85, FCF $8.9–$9.2B, revenue growth to the high-teens). The engine of the beat was the aftermarket: with 70,000+ engines in service (~70% of revenue is high-margin services) and a $210B+ backlog (~$170B of it contracted commercial services), GE is a razor-and-blades annuity firing on all cylinders. So the debate isn't quality — it's price. The stock has nearly doubled off its $255 low to ~$354, ~45x forward earnings and ~41x free cash flow. Even giving GE the optimistic aftermarket-compounder path (13%→7% FCF growth) AND a premium, quality discount rate, our owner-earnings DCF lands fair value near $290 — below today's price; on a textbook cost of equity (beta ~1.36) it's worth closer to the mid-$200s. A wonderful company with no margin of safety. Our call: HOLD, 3/5. We're not sellers of quality this good, but at 45x we wouldn't chase it — and we're notably more cautious than the Street's bullish ~$415 target (Buy, 24 of 35 analysts). Own it for the quality, add on real weakness in the low $300s, and watch the LEAP aftermarket. Not financial advice. THE CALL: HOLD (3/5, AN A-PLUS BUSINESS, PRICED FOR PERFECTION — A BEAT-AND-RAISE WITH NO MARGIN OF SAFETY) — base-case value ~$290 vs ~$354 today. What to watch: hard evidence the LEAP aftermarket is inflecting faster and more profitably than modeled — shop visits, spare-parts growth, and services margins accelerating together — which would justify the premium multiple and prompt an upgrade; the risk to respect is a downturn in air travel or a wave of order cancellations, which at ~45x earnings and ~41x FCF could re-rate the stock hard Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  8. 6d ago

    UNH Stock: UnitedHealth Crushed Earnings and Raised Guidance — Is the Crisis Over?

    UnitedHealth Group (UNH) Q2 2026 — UnitedHealth Group (UNH), the largest U.S. health insurer, reported a blowout Q2 2026: adjusted EPS of $6.38 crushed the ~$4.94 estimate and jumped 56% from $4.08 a year ago, as the medical care ratio fell to 86.7% (from 89.4%) and operating profit rose 55% to $8.0B. Management RAISED full-year adjusted EPS guidance to $19.50–$20.00 and doubled buybacks to $5B+. The stock (~$427, up on the print) has nearly doubled off its $235 low and sits ~7% off its $462 recovery high. The catch: revenue was flat, membership is shrinking (down ~1.6M YoY), the beat was flattered by an $860M reserve release, and a DOJ Medicare probe lingers. A year ago UnitedHealth was in free-fall — guidance pulled, a CEO change, surging medical costs, a Justice Department probe — and the stock crashed from over $600 to near $235. Q2 2026 is the clearest sign yet the crisis is over: adjusted EPS of $6.38 crushed the ~$4.94 estimate (up 56% YoY), the all-important medical care ratio fell to 86.7% from 89.4%, operating profit rose 55% to $8.0B, and, unlike its peers, management RAISED full-year guidance to $19.50–$20.00 and doubled buybacks to at least $5B. This is a genuine, high-quality turnaround from the best franchise in healthcare. But we can't pound the table: revenue was essentially flat, membership is shrinking (down ~1.6M YoY as it walks away from unprofitable business), the beat was flattered by an $860M favorable reserve release, and the DOJ Medicare overhang lingers. It's a margin-recovery-on-shrinking-membership story, and the stock has already nearly doubled off its low to ~22x forward earnings. Our owner-earnings work lands fair value near $450 (vs ~$427), modest upside and a touch below the Street's ~$459. Our call: HOLD, 3/5 — a real recovery, roughly fairly valued after a huge run. Own it for the quality, add on real weakness, and watch the medical care ratio. Not financial advice. THE CALL: HOLD (3/5, A REAL TURNAROUND, NOW ROUGHLY FAIRLY PRICED — A QUALITY BEAT WITH AN ASTERISK) — base-case value ~$450 vs ~$427 today. What to watch: the medical care ratio continuing to fall on clean, reserve-free quarters — the proof the recovery is durable and not a one-off; the risk to respect is a flare-up in the DOJ Medicare probe or any walk-back of the raised guidance, either of which reopens the crisis narrative Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

See All (1K)

About

⚡ Charged Alpha — The S&P 500 Stock Encyclopedia Data-driven deep dives into every stock in the S&P 500 after every earnings report. Each episode breaks down one company from open to close: what they do, how the numbers look, what Wall Street thinks, the bull case, the bear case. 🛠️ Check out our free beginner-friendly screening tools for stocks, ETFs, options, crypto, bonds, REITs & more at https://chargedalpha.com — no signup, no paywall. 📊 What you get in every episode: Company overview & competitive moat Full financial breakdown — valuation, revenue, margins, cash flow Analyst consensus & price targets Bull case vs. bear case Peer comparison, options flow & insider activity Key metrics to watch ⚠️ Not financial advice. For educational purposes only. Episodes are researched, written, and produced using AI-assisted tools. All data aggregated from publicly available sources. #stocks #investing #S&P500 #stockanalysis #chargedalpha #financialdata #earningsreport #earnings

Information

You Might Also Like